Who are Prevention of Venous Thromboembolism's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hympavzi, Eliquis, Xarelto, Heparin Sodium In Plastic Container, Nebulized heparin and salbutamol, Active Comparator: Rivaroxaban+Clopidogrel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/prevention-of-venous-thromboembolism.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Prevention of Venous Thromboembolism — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of Venous Thromboembolism (Prevention of Venous Thromboembolism) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant. Area: Cardiovascular.

phase 3 Anticoagulant Factor Xa Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Prevention of Venous Thromboembolism (Prevention of Venous Thromboembolism) — Prof. Stavros Konstantinides, MD. This drug prevents the formation of blood clots in the veins by inhibiting the coagulation cascade.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Prevention of Venous Thromboembolism TARGET	Prevention of Venous Thromboembolism	Prof. Stavros Konstantinides, MD	phase 3	Anticoagulant	Factor Xa
Hympavzi	MARSTACIMAB	Pfizer Inc	marketed	Monoclonal Antibody	Factor Xa	2025-01-01
Eliquis	apixaban	Bristol-Myers Squibb	marketed	Factor Xa inhibitor	Factor Xa (FXa)	2012-01-01
Xarelto	rivaroxaban	Johnson & Johnson	marketed	Direct Factor Xa Inhibitor	Factor Xa (FXa)	2011-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anti-coagulant	Antithrombin III, Factor Xa, Factor IIa	1939-01-01
Nebulized heparin and salbutamol	Nebulized heparin and salbutamol	Ain Shams University	marketed	Combination therapy: anticoagulant + bronchodilator	Heparin: Factor IIa and Factor Xa; Salbutamol: Beta-2 adrenergic receptor
Active Comparator: Rivaroxaban+Clopidogrel	Active Comparator: Rivaroxaban+Clopidogrel	Chinese Academy of Medical Sciences, Fuwai Hospital	marketed	Anticoagulant + Antiplatelet combination	Factor Xa; P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2034-02-17 — Xarelto · 9539218 · Method of Use · US
2034-08-17 — Xarelto · 9539218*PED · Compound · US

Sponsor landscape (Anticoagulant class)

Fresenius Kabi · 4 drugs in this class
University of Sao Paulo · 3 drugs in this class
Beijing Anzhen Hospital · 2 drugs in this class
San Filippo Neri General Hospital · 2 drugs in this class
Yong Seog Oh · 2 drugs in this class
CCRF Consulting Co., Ltd. · 1 drug in this class
Boston Scientific Corporation · 1 drug in this class
Beijing Suncadia Pharmaceuticals Co., Ltd · 1 drug in this class
Faculty Hospital Kralovske Vinohrady · 1 drug in this class
Deutsches Herzzentrum Muenchen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Prevention of Venous Thromboembolism — Competitive Intelligence Brief. https://druglandscape.com/ci/prevention-of-venous-thromboembolism. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab